2026-10-18T23:16:11Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/121002026-10-18T20:56:42Zopenairedrivercom_ebyu_10000col_ebyu_10001

Effect of Tocilizumab Use on Mortality in COVID-19 Patients Admitted to Intensive Care Unit; [Yoğun Bakım Ünitesine Kabul Edilen COVID-19 Hastalarında Tocilizumab Kullanımının Mortalite Üzerine Etkisi]Tosun, MustafaÖlmez, HasanCOVID-19cytokine storminterleukin 6mortalitytocilizumabacute phase proteinalanine aminotransferaseantibiotic agentaspartate aminotransferaseC reactive proteincholesterolcreatinineD dimerdexamethasoneenoxaparinfavipiravirferritinfibrinogenhigh density lipoproteinlactate dehydrogenaselactic acidlow density lipoproteinmethylprednisoloneprednisoloneprocalcitonintriacylglyceroladult respiratory distress syndromeagedAPACHEArticleAim: Coronavirus disease 2019 (COVID-19) mostly proceeds with mild respiratory symptoms, but sometimes severe pneumonia, cytokine storm, and acute respiratory distress syndrome can develop. Anti-cytokine treatments are being tried for cytokine storm. In this study, we aimed to examine the effect of tocilizumab on mortality associated with COVID-19. Material and Methods: The study included 146 patients with moderate-to-severe acute respiratory distress syndrome diagnosed with COVID-19. The patients were divided into two groups, receiving only standard treatment (ST group, n=44), and tocilizumab treatment in addition to standard treatment (TCZ group, n=102). Groups were compared in terms of demographic, clinic, and laboratory data. Also, mortality rates were determined to detect the effect of tocilizumab on mortality. Results: Overall, 36.3% (n=53) of the patients were female, 63.7% (n=93) were male, and the mean age was 69.5±14.2 years. The mortality rate was 29.4% (n=30) in the TCZ group and 52.3% (n=23) in the ST group (p=0.009). While C-reactive protein, fibrinogen, and lactate levels on admission to the intensive care unit (ICU) were similar across the groups, the TCZ group had higher ferritin levels (p=0.006). On discharge from ICU, the TCZ group had a significant decrease in C-reactive protein (p<0.001), while their ferritin levels decreased to levels in the ST group (p=0.134). The absence of tocilizumab in the treatment regimen was associated with a 2.63-fold increase in the mortality risk. Conclusion: Tocilizumab reduces the mortality in COVID-19 patients in ICU. However, further studies are warranted to better elucidate the efficacy and side effects of tocilizumab. © 2022, Duzce University Medical School. All rights reserved.Duzce University Medical School2022Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12100https://doi.org/10.18678/dtfd.11083031307-671XenDuzce Medical Journalinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12100